Podcasts about cme

Meet the Fantastic—and Controversial—Dr. David Healy Psychiatric Drug Companies-- What Are They NOT Telling Us? Today, we are thrilled to interview the famed and courageous Dr. David Healy. I have admired his work for many years, but never imagined I'd have the chance to meet him and chat with him. First things first. You may know Dr. David Healy for some of his highly controversial books, like "The Antidepressant Era," "Let Them Eat Prozac," and "Pharmageddon." But who is he, really? According to AI, Dr. David Healy is a prominent Welsh psychiatrist, psychopharmacologist, and critic of the pharmaceutical industry known for his research on antidepressants, their links to suicide, and exposing industry practices like ghostwriting and disease-mongering, operating through initiatives like RxISK.org to promote drug safety. He has a long history of challenging Big Pharma, facing academic backlash (like losing a University of Toronto post) for his views, and serving as an expert witness in legal cases involving psychotropic drugs, advocating for greater transparency and patient safety.  Healy initially worked with pharmaceutical companies, gaining firsthand knowledge of how SSRIs were marketed despite their trial weaknesses, focusing on the oversimplified serotonin hypothesis. He then became a vocal critic, highlighting issues like ghostwriting articles and manipulating academic opinion to sell drugs, leading to conflicts with industry-funded institutions. He founded RxISK.org, a platform for patients to report adverse drug reactions, aiming to make medicines safer. His strong stance (on research linking SSRI antidepressants to increased suicidal thoughts and urges) led to intense and corrosive controversy, including losing a professorship at the University of Toronto (though later settled as a visiting role) and harassment, noted here and here. In recent years, he has acted as an expert witness in cases involving drug-related suicides and homicides, bringing issues to regulators.  In essence, Dr. David Healy is a significant, often controversial, figure dedicated to drug safety, academic integrity, and patient awareness in psychiatry, challenging established narratives and industry power.  Taking a deeper dive, AI has added this critically important information: David Healy has discussed numerous examples of conflicts of interest that mainly involve the influence of the pharmaceutical industry on medical research, publication, and practice.  Key examples he has highlighted include: Ghostwriting of Articles: Pharmaceutical companies hire medical communication firms to draft research articles or reviews, and then get prominent academics or clinicians to put their names on the papers as the sole or primary authors, a practice known as ghostwriting. The named authors often have little to no involvement in the actual research or writing. Hiding or Misrepresenting Data: Drug companies have concealed unfavorable data or miscoded raw data on drug risks, such as the link between antidepressants and suicidal acts. This manipulation can make a drug appear safer or more effective than it actually is. Biased Clinical Trial Design: Healy notes instances where clinical trials are designed with "tricks," such as using inadequate or excessive doses of comparison medications to make the company's own drug look superior. Marketing-Driven Education: A large portion of continuing medical education (CME) classes for doctors are sponsored by industry. Healy argues this leads to a bias in the information presented to doctors, with an emphasis on the benefits of brand-name drugs rather than an objective assessment of all treatment options. Gifts and Payments to Physicians: Drug companies spend billions annually on marketing directed at doctors, including free samples, sales visits, and small non-educational gifts or lunches. Healy points out that while many doctors believe these gifts don't affect their own prescribing, studies show they influence prescribing patterns and create subtle biases. Industry Influence on Academia: Healy's own experience with a job offer being rescinded at the University of Toronto, which had received a large donation from a drug company (Eli Lilly), is a prominent case he uses to illustrate how industry funding can infringe upon academic freedom and stifle critical research. "Disease Mongering": Healy argues that the pharmaceutical industry often engages in "disease mongering," marketing conditions to the public and physicians to create a market for their products rather than simply addressing genuine medical needs.  So that hopefully gives you some idea of the scope of his work, and his vision of transparency and integrity in the reporting one the effectiveness and risks of psychotropic medications. In our conversation today, he emphasized the importance of listening to patients who describe side effects of medications, such as SSRIs, in described the efforts of Big Pharma to suppress such complaints, giving psychiatrists "talking points" to reassure and quiet concerned patients. In general, a main focus of his career has been to challenge and confront the efforts of drug companies to suppress negative information about their products and troublesome and dangerous side effects. He said that one of the rationales the drug companies use is to say that disseminating that type of information will discourage many potential patients from using their products, and therefore miss out on the potential benefits of the medications. In fact, they have a name for this, "treatment hesitancy," and discourage open discussion of negative effects for this reason. I asked Dr. Healy if he's experienced direct negative pushback from drug companies, and he gave a surprising answer—he said no, that the major pushback he's gotten has actually been from colleagues—psychiatrists who have bought the party line disseminated by the drug manufactures. For example, when he gave his famous talk at the University of Toronto on the increase in suicidal urges associated with SSRI antidepressants, a famous psychopharmacologist, Dr. Charlie Nemeroff, got him fired. Here's the story on Dr. Nemeroff, According to AI: In the late 2000s, Nemeroff faced investigations and sanctions from Emory University for failing to disclose significant speaking and consulting fees from pharmaceutical companies like GlaxoSmithKline, raising questions about research integrity and conflicts of interest, notes The BMJ and The New York Times.  Although the antidepressant effects of SSRIs are controversial and hotly debated, their effects on the nervous system are not. Dr. Healy's research indicates that they have a suppression effect on the nervous system, which dulls the senses, and this can happen within 1 to 2 days. One of the more troublesome of these effects is called "genital numbing," which affects 9 out of 10  people talking SSRIs. This can result in difficulties with sexual arousal and greatly delayed orgasm, and apparently these effects can persist long after drug discontinuation. He said that these sensory effects can develop quickly, within a day or two of starting the medications. Even more chilling, he said that the problem can actually get worse when you discontinue the medication, and can sometimes persist for life. In addition, quite a few individuals have "bad trips" on SSRIs, although a minority clearly have "good trips." He said the best thing to do for a bad trip is to take the patient off of the medication immediately—and NOT increase the dose. He confirmed my impression that a common error with all antidepressants is to increase the dose—which simply increases the side effects. In addition to the genital numbing described above, he said the SSRIs cause "emotional numbing," which means a decreased capacity for joy as well as sorrow. One of the main activities in David Healy's life has been listening to patients, rather than discounting their complaints when they describe negative effects of medications. When asked about what alternatives to drugs he might recommend to someone struggling with depression, he said that sometimes, just doing nothing will be helpful, since most mood problems clear up spontaneously in 12 to 14 weeks. He said that most are simply human problems, not "mental disorders," but real-life problems, like relationship conflicts or social issues. Although we did not discuss it extensively on the show, I would point out that skillful, drug-free therapy with TEAM CBT can sometimes help as well, and that recent research has confirmed rapid often dramatic mood improvements with individuals using the Feeling Great app, which has been entirely free to anyone since the summer of 2025.  Finally, we do not advise anyone to discontinue or modify the dosages of any medications you have been prescribed without consultation with your doctor. The information in the Feeling Good podcast is of a strictly educational nature, and is not intended as treatment or medical advice. We thank you for listening to today's shocking but incredibly important dialogue with one of the pioneers and champions of greater ethical integrity and transparency in the psychiatric profession. It is sad, indeed, that we don't have more visionary critical thinkers like Dr. David Healy! David (H), Rhonda, and David (B)

Featuring perspectives from Prof Nicoletta Colombo and Dr Kathleen N Moore, including the following topics: Introduction (0:00) Promising Novel Agents and Strategies Under Investigation in Ovarian Cancer (2:35) Current Management of Newly Diagnosed and Relapsed/Refractory Ovarian Cancer(41:48) CME information and select publications

Prof Nicoletta Colombo and Dr Kathleen N Moore discuss the selection and sequencing of therapy for patients with ovarian cancer and summarize major advances in the treatment landscape over the past year.CME information and select publications here.

Host Dr. Andrew Pouw welcomes Drs. Gustavo De Moraes, Aakriti Shukla, and Simon John to discuss their team's work spanning the full arc of nicotinamide as a neuroprotection candidate for glaucoma, from bench to clinical trials. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Beef production continues restrained to keep prices up and packer losses as small as possible. 516K head produced last week, same as the previous week. Heading into spring this is keeping the beef supply tight and prices supported. We have the smallest beef herd since 1951 when there were half as many people in the country. That is not turning around anytime soon. Regarding current market prices, everything is going up. Ribeyes and strip loins will be leading prices higher for the next few weeks. Grind demand is strong and prices moving up as well. Chuck had a nice few weeks of declines, that is over, rounds never lost support and continue to move higher. I do think middle meats and thin meats, flanks, skirts, sirloin flap, will all be tight and expensive, already looking at Cinco de Mayo.  We are at the start of a steady move higher, I'd advise buy sooner, rather than later, waiting will cost you money. Keep well ahead of your needs, this market is going to be expensive and tight.Poultry production continues to run about 2% ahead of last year. Demand is good, production is strong, pricing is holding up, though wings declined a second week in a row. Boneless skinless breasts and tenders… holding steady. It's a good time to menu chicken. On the Avian flu front, its ugly. 23 new cases reported in the last week affecting 4.8Millioin birds, 4 million of those birds were egg layers. I'm not feeling good about spring migration.Soy markets continue to climb. Its been so long since we've seen a bull market in soy. Soy oil and canola oil, both moving higher with good export demand and higher biofuel usage. We may see this plateau in the next couple weeks, but right now, soy is on a tear. Corn and wheat… not so much . Still trading sideways and I don't see that changing.Pork bellies continue to march higher, today's close $153 up from last week $148. I don't think we are done by any stretch. Bacon will be going up. Contrary to rest of the pork complex, plenty of inventory, prices are good. Yes, menu pork.Butter took a huge run up this week. Thru Thursday's close on the CME butter is up 24! That's a big move. Barrel and block both up 3 but butter is the big mover. We'll see if the markets hold these recent gains, but for now all signs point to a higher dairy costs.Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

In this episode, Tracey Davidoff, MD and Joe Toscano, MD discuss the February 2026 Evidence-Based Urgent Care article, Urgent Care Evaluation and Management of Constipation02:18 Why Constipation Matters03:36 Three Patient Categories06:28 Constipation Myths07:19 X-rays And Docusate09:42 What Is Normal12:12 Red Flags And Mimics15:34 Rectal Exam Decisions17:08 Enemas And Disimpaction20:20 Urgent Care Logistics21:05 Constipation vs Pain23:34 Appendicitis Cautionary Tale24:42 Treatment Ladder Basics26:13 Polyethylene Glycol Power29:26 Stercoral Colitis30:46 Normal Bowel Habits31:55 Bottom Line Red Flags33:30 When Its Not Constipation36:27 Wrap Up and Next Topics???? Subscribers, take the CME test here.✅️ Not a subscriber? Join here!

Link for CME credit coming soon! This episode follows Lisa and Craig Wilkerson as they share their son Ryan's sudden, severe decline from sudden-onset OCD-like symptoms to full disability caused by PANS/PANDAS, and the family's multi-year struggle to get proper medical care. They describe repeated misdiagnoses, traumatic hospital experiences, and even CPS involvement, until Dr. Anthony Infante used specialized testing and prescribed IVIG immunotherapy. The treatment gradually restored Ryan's sleep, hygiene, social life, and independence. Listeners and viewers will hear clinical pearls about listening to families, considering autoimmune causes for acute neuropsychiatric changes, and the role of multidisciplinary care and targeted immune testing and treatment.

Host: Stephanie Christenson, MD Guest: Diego Maselli, MD, FCCP COPD is increasingly recognized as a heterogeneous disease, and for a subset of patients, type 2 inflammation plays a meaningful role in exacerbation risk and treatment response. Given that, Drs. Stephanie Christenson and Diego Maselli come together to examine how insights into the pathobiology of type 2 inflammation can directly inform clinical decision making in COPD. Specifically, they discuss the practical use of blood eosinophil counts to phenotype patients, assess risk, and guide therapy selection within the context of GOLD 2025 and 2026 guidance. Dr. Christenson is an Associate Professor at the University of California San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, and Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health in San Antonio. This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Zach Mercurio, Ph.D., is a researcher, author, and speaker who specializes in purposeful leadership, mattering, meaningful work, and positive organizational psychology.He wrote "The Invisible Leader: Transform Your Life, Work, and Organization with the Power of Authentic Purpose." His forthcoming book, "The Power of Mattering: How Leaders Can Create a Culture of Significance," will be released by Harvard Business Review Press in 2025.Zach works with hundreds of organizations worldwide to forge purposeful leaders who enable mattering, motivation, well-being, and performance. Some of his clients include the U.S. Army, USA Wrestling, J.P. Morgan Chase, Delta Airlines, Marriott International, The Government of Canada, and The National Park Service.He also serves as one of author Simon Sinek's “Optimist Instructors.”Zach earned his Ph.D. in organizational development from Colorado State University where he serves as a Research and Teaching Fellow in the Department of Psychology's Center for Meaning and Purpose and as an Instructor in the Organizational Learning, Performance, and Change program.His research on meaningful work has been awarded by The Association for Talent Development, The Academy of Management, and The Academy of Human Resource Development.Zach lives in Fort Collins, CO with his wife, two sons, and two adopted dogs.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers;  The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Send a textThe Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson | Proudly Produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. We explore practical wins and bold ideas across supportive care, colorectal cancer prevention, immunotherapy timing, digital triage and equity. From halving hot flushes with an NK1/NK3 blocker to biomarker-guided aspirin in colon cancer, we weigh value, risk and what truly improves lives.• Elinzanetant cutting severe hot flushes and improving treatment adherence• Current non-hormonal options and gaps in symptom control• Biomarker-selected aspirin reducing recurrences in colorectal cancer• Limits of DFS, toxicity trade-offs and subgroup signals• Rising early-onset colorectal cancer and system planning needs• Possible environmental and microbiome drivers under study• ASCO geriatric assessment guidance and G8 screening in clinics• PD-1 with short-course radiotherapy boosting rectal pCR rates• Large language models for safe, efficient symptom triage• Rare cancers report on access, cost, and rural inequities• Telehealth standards to link expertise closer to home• Healthy workplace culture to retain a resilient oncology workforceJoin the Oncology Network, registration is free, and leave us a voice note on the OJC page at oncologynetwork.com.au. Physicians, don't forget you can claim CME points for listening to the show!Thanks for listening

Crain's residential real estate reporter Dennis Rodkin joins host Amy Guth top talk news from the local market, including a new poll that found housing costs now top crime as Chicago voters' biggest concern. Plus: American blames United's "reckless scheduling" for O'Hare woes, CME and Cboe shares rallied to record high as volumes surge on Iran war, Oak Brook retail center sold for $44 million and Chicago Fire FC breaks ground on new South Loop stadium. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Struggling to balance a demanding medical career with a healthy marriage? It might be more common than you think. In this part one of two eye-opening episode of Succeed In Medicine podcast host Dr. Bradley Block interviews Dr. Michael F. Myers, as they delve into frequent issues in physician marriages, including communication gaps, workaholism, and using work as an escape from home tensions. Dr. Myers shares insights on recognizing when overwork crosses into avoidance, the impact of poor role models from past generations, and practical ways to transition from work mode to family presence. Key discussions include protecting couple time amid busy schedules, handling defensiveness in conversations, and fostering intentional dates or "grown-up time" away from kids. They also touch on generational shifts in medicine, where younger physicians prioritize life balance over endless dedication, and the importance of transparency about personal costs of overwork. Dr. Myers emphasizes treating marital communication as a skill to master, like medical training, and highlights resources like retreats for enrichment. Whether you're a physician navigating marital discord or supporting a partner in medicine, this episode offers compassionate guidance to prevent burnout at home, strengthen relationships, and model healthy dynamics for kids, setting the stage for part two next week. Three Actionable Takeaways: Protect Couple Time Intentionally: Schedule uninterrupted "grown-up time" daily e.g., 30 minutes post-work with no distractions like TV or phones, or bi-weekly dates even low-cost walks; train kids to respect boundaries to rebuild connection beyond co-parenting, reducing feelings of drifting apart. Create a Work-to-Home Transition Ritual: Build in buffer time after shifts, whether a commute unwind, quick run, or quiet moment to shift from decisiveness at work to presence at home; recognize when exhaustion is temporary and communicate needs to avoid guilt or resentment. Listen Without Defensiveness: When a spouse flags overwork or avoidance, pause and reflect instead of rationalizing; treat communication as a learnable skill like medicine, seeking resources like marital retreats or therapy to address root issues before they escalate to fights or disconnection. About the Show: Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school! About the Guest: Dr. Michael F. Myers is a professor of clinical psychiatry and recent past vice president of education and director of training in the Department of Psychiatry and Behavioral Sciences at SUNY Downstate Health Sciences University in Brooklyn. He's a specialist in physician health and the author of many books, including "Physicians with Lived Experience: How Their Stories Offer Clinical Guidance" and "Doctors' Marriages: A Look at the Problems and Their Solutions." He lectures widely on stresses in medical training, burnout, moral injury, depression, substance use, PTSD, marital discord, and reducing stigma in medicine. Connect with Dr. Michael Myers: Website: https://www.michaelfmyers.com About the Host: Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physicians Want to be a guest? Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more! Socials: @physiciansguidetodoctoring on Facebook @physicianguidetodoctoring on YouTube @physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00) Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32) Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52) Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46) CME information and select publications

Send a textThere's a moment that many successful medical practices reach where something feels… off.Volume is up. The practice is growing. On paper, things look good—sometimes even great. And yet, the day-to-day experience feels harder than it used to. Communication takes more effort. Decisions feel heavier. Small issues seem to snowball faster than expected.Instead of growth feeling energizing, it starts to feel exhausting.That's the moment we're talking about today. Because growth is supposed to make things better, not more chaotic. And when success starts creating friction inside a practice, it's not a sign that something is wrong—it's a sign that the practice is changing.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/

In this KE Report Daily Editorial, I am joined by Darrell Fletcher, Managing Director of Commodities at Bannockburn Capital Markets. As geopolitical tensions escalate following the outbreak of war in Iran and the critical shutdown of the Strait of Hormuz, Darrell provides a high-level perspective from the commodities trading desk on how these events are reshaping global markets. The discussion dives deep into the immediate and long-term impacts on the energy complex, the surprising resilience of certain metals, and the technical hurdles currently facing major exchanges.  Key Discussion Points: The Strait of Hormuz Crisis: Analyzing the impact of shutting down a corridor that handles 20% to 25% of global oil and 20% of liquefied natural gas (LNG). Energy Market Dynamics: Why the current move in crude oil ($WTI and $BRENT) remains "muted but guarded" due to a global oversupply of 3 to 3.5 million barrels per day. Aluminum's Surprise Surge: How Middle Eastern production represents 10% of global output, causing aluminum prices to spike while other base metals remain under pressure from a strong USD. Natural Gas Divergence: Understanding why European (TTF) and Asian (JKM) gas prices are skyrocketing while U.S. Henry Hub prices remain relatively stable due to export capacity limits. CME Exchange Outages: A look at recent technical outages at the CME and what they mean for trader confidence during high-stakes geopolitical events.   Click here to learn more about Bannockburn Capital Markets  - https://www.bannockburnglobal.com/   -------------------------- For more market commentary & interview summaries, subscribe to our Substacks:  The KE Report: https://kereport.substack.com/  Shad's resource market commentary: https://excelsiorprosperity.substack.com/ Investment Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security or investment product. Investing in equities, commodities, really everything involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Featuring perspectives from Dr Hope S Rugo and Dr Sara M Tolaney, including the following topics: Introduction: Long-Term Outcomes with Antibody-Drug Conjugates (0:00) HER2-Positive Breast Cancer (8:02) HER2-Negative Breast Cancer (32:41) CME information and select publications

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.CME information and select publications here.

CME outage before first notice day sparks gold market manipulation fears as physical demand surges and East challenges Western price control. What are the odds that the world's largest gold and silver derivatives exchange suddenly experiences a “technical outage” right before first notice day? Questions on Protecting Your Wealth with Gold & Silver? Schedule a Strategy Call Here ➡️ https://calendly.com/itmtrading/podcastor Call 866-349-3310 

Comex Gold Delivery Was Discouraged From The Beginning With rumors swirling around the CME's latest "technical glitch" ahead of another delivery cycle, what we can say with certainty is what was revealed by some WikiLeaks cables about the formation of the COMEX gold market back in the 70s, and the true intention behind the system we currently have. David Morgan walks through the key document, and to find out more about this hidden piece of history, click to watch this video now! - To get access to David's fantastic research at “The Morgan Report” go to: https://www.themorganreport.com/membersportal/aff/go/ArcadiaEconomics - Join our free email list to be notified when a new video comes out: click here: https://arcadiaeconomics.com/email-signup/ - Follow Arcadia Economics on twitter at: https://x.com/ArcadiaEconomic - To get your copy of 'The Big Silver Short' (paperback or audio) go to: https://arcadiaeconomics.com/thebigsilvershort/ - #silver #silverprice #gold And remember to get outside and have some fun every once in a while!:) (URL0VD)Subscribe to Arcadia Economics on Soundwise

In this episode, Sam Ashoo, MD and T.R. Eckler, MD discuss the February 2026 Emergency Medicine Practice article, Emergency Department Diagnosis and Management of Acute Coronary Occlusion00:00 - Introduction & Welcome01:21 - Episode Overview: Acute Coronary Occlusion02:06 - Why This Topic Matters: Statistics & New Guidelines03:35 - Nomenclature: ACO vs STEMI/NSTEMI06:15 - Differential Diagnosis for STEMI07:41 - Pre-Hospital Care & EMS Role11:37 - Patient History & Presenting Symptoms12:28 - Physical Examination Findings14:54 - EKG: The Most Important Test17:00 - STEMI Definition & Criteria20:32 - STEMI Equivalents: Scarbosa Criteria22:40 - Smith Modified Scarbosa Criteria24:10 - Hyperacute T Waves25:30 - Posterior STEMI28:40 - De Winter Sign29:38 - Non-STEMI EKG Findings31:30 - AVR ST Elevation32:47 - Wellens Syndrome33:54 - Reciprocal ST Segment Changes36:15 - Inferior MI Patterns37:54 - Laboratory Testing39:51 - Imaging: Chest X-Ray & Echocardiography42:25 - Supplemental Oxygen: What the Evidence Shows44:50 - Analgesia & Pain Management46:35 - Pharmacotherapy: Aspirin & Antiplatelet Agents49:18 - Reperfusion Therapies & Thrombolytics53:05 - Cardiac Arrest in STEMI Patients53:55 - Closing Remarks & CME InformationSubscribers, take the CME test here.Emergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net

Listen in as our expert panel reviews important concepts behind antimicrobial stewardship along with tips to help limit unnecessary antimicrobial use.Special guests:Madeline King, PharmD, MPH, BCIDPCo-Director, Outpatient Antimicrobial StewardshipCooper University Health CareAssistant Professor of MedicineCooper Medical School at Rowan UniversityMichael A. Deaney, PharmD, AAHIVPInfectious Diseases Clinical Pharmacy SpecialistDenver Health & Hospital AuthorityYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science University For the purposes of disclosure, Dr. Madeline King reports a relevant financial relationship with Shionogi (speakers bureau for cefiderocol).The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in January 2026.Use code mt1026 at checkout for 10% off a new or upgraded subscription.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Toolbox: Antimicrobial StewardshipAlgorithm: Investigating Possible Drug AllergyCE Course: Implementing Rapid Diagnostic TestingChart: Antibiotic Therapy: When Are Shorter Courses Better?Send a text*****

Forty years ago, when I was trading eurodollar interest rate futures, it was routine to respond to a sudden unexplained move in the market by calling the floor of the CME and talking to our broker. Caught up in the excitement of the loud heaving mass of brokers and locals in the pit*, he would […]

Click Here,Text Us,Get a Shout-Out next episode.Start with a smile and stay for the substance—we pair the spark of the Fire Horse year with a hands-on guide to listening smarter, supporting freely, and joining a community that talks back. We kick off with the Chinese zodiac, comparing traits for Tiger, Rat, Snake, and Dragon and unpacking what cultural archetypes offer beyond fortune-cookie fate. The result is a grounded take on identity and timing, with a dash of humor and a nod to global celebrations.From there, we get practical. We walk through how podcast 2.0 apps make following easier, auto-downloads safer for commutes, and feedback faster with built-in messaging and boosts. You'll hear exactly where to find our episodes, how to send a quick text or voice note, and simple ways to support through Buy Me a Tea, PayPal, sats on Lightning, or Cash App. Our site ties it together with early posts, photos, and a SpeakPipe button that turns a hello into something we can share on-air.We also deliver a crisp seven-day earthquake report: totals across magnitudes, a trio of 6.0+ events including a 7.1 near Malaysia, and context along the seismically active arcs. Then we look up—sunspots are rebounding, a recent CME points to a likely G1 geomagnetic storm, and radio conditions are shifting in ways hams and skywatchers will notice. On the spacefront, Artemis slips again, but there's a bright human touch: NASA now lets astronauts bring smartphones to the station, promising more personal photos and video from orbit.If you value open shows without paywalls, this one's for you. Follow on your favorite player, try a podcast 2.0 app for extra features, share the episode with a friend, and send us a message or boost to shape what we explore next. Your voice fuels the flock—subscribe, leave a review, and tell us your zodiac sign and why it fits.Support the show I hope you enjoy the show! We believe in Value4Value for the podcaster and the listener alike. If you find value in our show, Come back, and tell a friend. Sharing the podcast with someone is a very good way for us to grow. Pray for us. Contact Us. Email: theuglyquackingduck@gmail.com. Text us: On a podcast 2.0 player you will find a link under the episode description. Leave a voice message: On our “Comment” page there is a link to record your voice. Just letting us know you are out there listening is a big boost! Help us with ideas, technology, art work, etc. Support us financially. The equipment, the Podcast hosting, the web page all costs. “Support the Podcast” Anyway you can support us is very much appreciated! Thank You. Until Next time.73 and may the Father's love go with you.Bruce Email: theuglyquackingduck@gmail.comWebsite: https://theuglyquackingduck.com/

Click Here,Text Us,Get a Shout-Out next episode.Start with a smile and stay for the substance—we pair the spark of the Fire Horse year with a hands-on guide to listening smarter, supporting freely, and joining a community that talks back. We kick off with the Chinese zodiac, comparing traits for Tiger, Rat, Snake, and Dragon and unpacking what cultural archetypes offer beyond fortune-cookie fate. The result is a grounded take on identity and timing, with a dash of humor and a nod to global celebrations.From there, we get practical. We walk through how podcast 2.0 apps make following easier, auto-downloads safer for commutes, and feedback faster with built-in messaging and boosts. You'll hear exactly where to find our episodes, how to send a quick text or voice note, and simple ways to support through Buy Me a Tea, PayPal, sats on Lightning, or Cash App. Our site ties it together with early posts, photos, and a SpeakPipe button that turns a hello into something we can share on-air.We also deliver a crisp seven-day earthquake report: totals across magnitudes, a trio of 6.0+ events including a 7.1 near Malaysia, and context along the seismically active arcs. Then we look up—sunspots are rebounding, a recent CME points to a likely G1 geomagnetic storm, and radio conditions are shifting in ways hams and skywatchers will notice. On the spacefront, Artemis slips again, but there's a bright human touch: NASA now lets astronauts bring smartphones to the station, promising more personal photos and video from orbit.If you value open shows without paywalls, this one's for you. Follow on your favorite player, try a podcast 2.0 app for extra features, share the episode with a friend, and send us a message or boost to shape what we explore next. Your voice fuels the flock—subscribe, leave a review, and tell us your zodiac sign and why it fits.Support the show I hope you enjoy the show! We believe in Value4Value for the podcaster and the listener alike. If you find value in our show, Come back, and tell a friend. Sharing the podcast with someone is a very good way for us to grow. Pray for us. Contact Us. Email: theuglyquackingduck@gmail.com. Text us: On a podcast 2.0 player you will find a link under the episode description. Leave a voice message: On our “Comment” page there is a link to record your voice. Just letting us know you are out there listening is a big boost! Help us with ideas, technology, art work, etc. Support us financially. The equipment, the Podcast hosting, the web page all costs. “Support the Podcast” Anyway you can support us is very much appreciated! Thank You. Until Next time.73 and may the Father's love go with you.Bruce Email: theuglyquackingduck@gmail.comWebsite: https://theuglyquackingduck.com/

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00) Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13) Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21) Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46) Clinician Survey Results (32:16) Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39) Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20) Promising Investigational Strategies — Dr Chiang (49:14) CME information and select publications

Beef is tight. Bellies are climbing. Birds are under watch. The seasonal shift may bring more than warmer weather.BEEF: Production is down 10% YTD, with last week at just 516K head. The smallest herd in 75 years keeps supply tight as spring demand builds. Strips and ribeyes look ready to lead a March run – and thin meats may feel it first.POULTRY: Production is up 2%, but hatch rates under 79% raise questions. Wings dip while breasts hold steady. Thirteen new avian flu cases hit 550K birds – just as migration ramps up.GRAINS: Soy keeps climbing on export deals and biofuel demand. Corn and wheat stay stuck. Three weeks into the rally, and now we see if it has legs.PORK: Bellies jumped to $146, nearing $150 faster than expected. Bacon will follow, and elevated pricing could stick into summer. The rest of pork remains a value, but for how long?DAIRY: Barrel up 5. Block up 6. Butter up 7. Dairy is clearly moving higher, and it doesn't look finished yet.Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

Production is steady. Prices dipped. But nearly 5 million birds are gone – and migration season is just getting started.BEEF: Harvest rose to 541K head, but we're still running well behind last year. Middle meats are inching higher, especially strips, while chucks soften and grinds slip again (for now). Production isn't growing. Plan accordingly.POULTRY: Production is up 2% year over year, but the early-year price run just stalled. Wings, breasts, and tenders dipped slightly. Meanwhile, avian flu hit hard again, and spring migration could make things interesting.GRAINS: Soy oil is moving higher for a second straight week, surprising given the supply. Corn slipped back, wheat flat. Right now, soy has the spotlight.PORK: Bellies climbed again to $138 and still look headed higher. The rest of the complex is steady and balanced. Nothing dramatic… yet.DAIRY: Dairy has direction. Block jumped, butter keeps recovering, barrel ticking up. Momentum is building.Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.CME information and select publications here.

This new Pre-AA to CAA PROCESS series follows Brittany Robinson as her journey unfolds from 2024 through 2028, an ongoing conversation that captures the growth, the pivots, the waiting, and the wins along the way. It is about honoring growth as it happens and having the courage to tell your story before you know how it will end. This is the Pre-AA to CAA [PROCESS] of Britton Robinson.New to this series?ep. 89 Britton's Pre-AA to CAA Journey PART 1A HUGE Thank You to my Season 5 PROCESS sponsor, Harmony Anesthesia Staffing.Harmony is CAA-owned, clinician-forward, and leading the way in the CAA locums market. Schedule your free 15-min consult and see how locums can work for you. Say 'hi' to Rad and Sasi for me when you do!You can now text me! Leave your email if you need a response!Complete your required CAA CME credits with courses designed specifically for Certified Anesthesiologist Assistants. Visit cmeforcaas.com and use the code CME15 to receive 15% off any CME purchase.Stay Connected by subscribing to the Awakened Anesthetist Newsletter- for more CAA specific resources, exclusive content and offers. Watch episodes of Awakened Anesthetist Now on YouTube! Let's Chat! awakenedanesthetist.com or on IG @awakenedanesthetist

CME outage before first notice day sparks gold market manipulation fears as physical demand surges and East challenges Western price control. What are the odds that the world's largest gold and silver derivatives exchange suddenly experiences a “technical outage” right before first notice day?Questions on Protecting Your Wealth with Gold & Silver? Schedule a Strategy Call Here ➡️ https://calendly.com/itmtrading/podcastor Call 866-349-3310

At 12:15 pm CT yesterday, CME Globex Metals and Natural Gas futures and options markets were halted. Metals trading resumed about 90 minutes later. The CME blamed it on technical issues. We report new drill results from White Gold and Spanish Mountain Gold. We have the latest corporate updates from Great Pacific Gold, Talisker Resources and Equinox Gold. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Steve Nicoll is a trusted business excellence coach who helps turn bold ideas into lasting change. With decades of cross-industry experience, he's known for bridging strategy and action, whether in the boardroom or on the shop floor. Calm, engaging and grounded, Steve quickly builds trust and inspires teams to embrace improvement with energy and purpose. He listens deeply, empowers others, and delivers results. His strength lies in combining operational insight with natural leadership to help organizations gain clarity, and unlock confidence and capability to create real, sustainable impact. A Shingo Prize recipient and coach, Lean Fellow, and MSc in Sustainable Business Excellence, Steve brings deep expertise in leadership, lean thinking and cultural transformation.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics: Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00) Potential Utility of ctDNA Testing to Identify Patients with Localized CRC Who Might Benefit from Treatment De-escalation or Escalation — Dr Lieu (17:44) Role of ctDNA Analysis in the Management of Metastatic CRC – Dr Dasari (36:16) Clinical Investigator Survey Results (56:06) Case: A woman in her early 40s with mismatch repair-proficient/microsatellite-stable (MSS), low-risk Stage II colon cancer — Dr Lieu (1:23:05) Case: A woman in her early 70s with microsatellite instability-high Stage III colon cancer with a BRAF mutation — Dr Cohen (1:26:06) Case: A man in his mid 40s with metastatic CRC — Dr Dasari (1:31:57) Case: A man in his early 50s with low-risk Stage III colon cancer — Dr Lieu (1:37:54) Case: A man in his early 30s with MSS, high-risk Stage II CRC — Dr Cohen (1:50:17) Case: A woman in her early 50s with metastatic CRC — Dr Dasari (1:52:05) Case: A man in his early 60s with Stage IV colon cancer — Dr Lieu (1:56:05) CME information and select publications

Welcome to Perimenopause WTF!, brought to you by ⁠Perry⁠—the #1 perimenopause app and education space. The Perry Academy was created for

In this episode, Lillian Erdahl, MD, FACS, is joined by Jessica Liu, MD, MS, MPH, from the Department of Surgery, Harbor UCLA Medical Center. They discuss Dr Liu's recent article, “Identifying Diagnostic Gaps and Mitigation Strategies for Older Adult Emergency General Surgery Patients: A Scoping Review,” in which the authors identified the current diagnostic issues, clinical tools, and clinician feedback strategies in the older adult emergency general surgery (EGS) setting. While challenges unique to older adults exist, variability in the use of tools to improve identification of older adult conditions in EGS and gaps in feedback to improve diagnosis remain.   Disclosure Information: Drs Erdahl and Liu have nothing to disclose.   To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date.   Liu, Jessica K MD, MS, MPH; Peters, Xane D MD, MS; Remer, Sarah L MD; Beestrum, Molly MLIS; Cooper, Zara MD, FACS, MPH; Russell, Marcia M MD, FACS; Hall, Bruce L MD, FACS, PhD; Ko, Clifford Y MD, FACS, MSHS, MS. Identifying Diagnostic Gaps and Mitigation Strategies for Older Adult Emergency General Surgery Patients: A Scoping Review. Journal of the American College of Surgeons 241(5):p 904-916, November 2025. | DOI: 10.1097/XCS.0000000000001480   Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.   #JACSOperativeWord   Copyright © 2026 by the American College of Surgeons (ACS). All rights reserved.   The contents of these materials may be cited in academic publications but otherwise may not be reproduced, disseminated, or transmitted in any form by any means without the express written permission of ACS. These materials may not be resold nor used to create revenue-generating content by any entity other than the ACS without the express written permission of the ACS. The contents of these materials are strictly prohibited from being uploaded, shared, or incorporated in any third-party applications, platforms, software, or websites without prior written authorization from the ACS. This restriction explicitly includes, but is not limited to, the integration of ACS content into tools leveraging artificial intelligence (AI), machine learning, large language models, or generative AI technologies and infrastructures. 

Dr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.CME information and select publications here.

Dr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.CME information and select publications here.

What would you do if you opened your mail and saw a letter from the medical board? For many physicians, that moment triggers fear, shame, and a flood of worst-case scenarios. Even a single patient complaint can feel like your entire career is suddenly on the line. And because most of us were never trained on how medical board investigations actually work, the uncertainty can be overwhelming. In today's episode, I'm joined by Guillermo Beates, Esq., a seasoned healthcare attorney and partner at Friar Levitt, who works closely with physicians facing medical board investigations, licensing issues, audits, and administrative actions. Guillermo pulls back the curtain on a process that often feels mysterious, intimidating, and isolating—and explains what physicians really need to know to protect themselves and their careers. We talk honestly about why board investigations happen, what not to do if you're contacted, and how small missteps early on can snowball into much bigger problems. Most importantly, Guillermo shares a grounded, hopeful message: one investigation does not have to define your career. In this episode we're talking about: Common triggers for medical board investigations, including patient complaints, audits, and reports from other clinicians What different types of board notices mean, and how to "triage" them appropriately Why responding incorrectly (or not responding at all) can escalate a situation fast The risks of surrendering a license or DEA/CDS registration without legal guidance What consent orders are, and why they matter more than many physicians realize How investigations become public and what gets reported to the National Practitioner Data Bank Why fear and shame can push physicians to leave medicine prematurely, and why you don't have to Links for this episode: Frier Levitt - Professional Board Actions: https://www.frierlevitt.com/what-we-do/healthcare-law/professional-board-actions

Most people in CME and medical writing are using AI. Fewer have an actual workflow — something documented, repeatable, and defensible enough to explain to a client or compliance reviewer. This episode explores why that gap matters, what a staged workflow looks like in practice, and why this is becoming a professional differentiator right now.In this episode:Why "I try things and sometimes it works" is a ceiling, not a processThe difference between using AI and having an AI workflowWhat the 2026 MedComms Freelancing Barometer tells us about where the field is right nowWhy documentation and traceability are the parts most people skip — and why that's changingReady to build your workflow?The AI Practice Lab starts March 9th. Four weeks, eight live sessions, hands-on work with Núria Negrão PhD. You'll leave with a documented, repeatable AI workflow for research, drafting, and quality control — one you can confidently explain to clients and teams.→ Join the AI Practice LabMentioned in this episode:AI Practice LabBuild a Practical, Safe, Repeatable AI-assisted Workflow in Just 4 Weeks. March 9 - April 2 Move beyond experimenting with AI. In this 4-week practice lab, work hands-on with Núria Negrão to build a documented, repeatable AI workflow for research, drafting, and quality control—one you can confidently explain to clients and teams. This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Neurologic complications of hematologic disorders are frequently encountered in clinical practice and can involve both the central and peripheral nervous systems. Early recognition and appropriate management in collaboration with a hematologist are essential to reduce morbidity and mortality. In this episode, Kait Nevel, MD, speaks with Lauren Patrick, MD, and Mark Terrelonge, MD, MPH, authors of the article "Neurologic Complications of Hematologic Disorders" in the Continuum® February 2026 Neurology of Systemic Disease issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Patrick is an assistant professor of neurology at the University of California, San Francisco, in San Francisco, California. Dr. Terrelonge is an associate professor of neurology at the University of California, San Francisco, in San Francisco, California. Additional Resources Read the article: Neurologic Complications of Hematologic Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Full episode transcript available here Dr Nevel: Thick blood, thin blood. These are terms often used by patients and caregivers to describe some of the hematologic disorders that can lead to neurological diseases such as stroke. So, when should we consider a hematologic disorder as a potential cause for neurological conditions, such as stroke or neuropathy. Today I have the opportunity to interview Drs Lauren Patrick and Mark Terrelonge to learn more about neurologic complications of hematologic disorders in their recent article in Continuum. Dr Jones: This is Dr Lyell Jones, editor-in-chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today I'm interviewing Drs Lauren Patrick and Mark Terrelonge about their article on neurologic complications of hematologic disorders. This article appears in the February 2026 Continuum issue on neurology of systemic disease. Welcome to the podcast, and please introduce yourself to the audience. Dr Patrick: Thank you for having us. We're both thrilled to be here. I'm Lauren Patrick, a vascular neurologist and assistant professor at the University of California, San Francisco, and program director for the Vascular Neurology Fellowship here. Dr Terrelonge: And I'm Mark Terrelonge, I'm an associate professor of neurology and neuromuscular medicine here at UCSF and one of the associate program directors for the adult neurology residency. Nice to meet you. Dr Nevel: Nice to meet you both. Really looking forward to getting into your article and learning more. So, to kind of kick us off, I always like to ask what do you think is the most important takeaway from your article for the practicing neurologist? And maybe since there are two of you and I suspect you covered slightly different aspects of this article, maybe you could give us two most important takeaways. Dr Patrick: Sure. I think the biggest takeaway is to keep hematologic disorders on the differential when evaluating patients with neurologic symptoms. Conditions like sickle cell disease, myeloproliferative neoplasms, or plasma cell dyscrasias and paraproteinemia can cause strokes or peripheral neuropathies, and many have specific and targetable treatments. The early recognition and collaboration with our hematology colleagues can truly change patient outcomes, whether that's by initiating cytoreductive therapy, managing thrombocytopenia, or optimizing antithrombotic therapy. Dr Nevel: Great. So, this is a really big and diverse topic. As always, I'm going to urge our listeners to read the article because there is a lot of really good stuff in your article that we just don't have time to get into during this interview today. But you cover a lot of different hematological disorders and how they can cause neurological complications. One of the major neurological complications of hematological disorders is cerebral vascular events. So, I'm hoping, Warren, that you can walk us through a little bit. When should we consider workup of potential hematologic disorder as a cause when we see a patient with ischemic stroke, because certainly not all patients with ischemic stroke should be getting a broad hematological disorder work up. So how can we kind of identify early on that there might be something else at play? Dr Patrick: Absolutely, great question. So, in many cases, the underlying hematologic disorder is already known, such as sickle cell disease or polycythemia vera. But sometimes stroke is the initial presentation or manifestation of the disease. So red flags can include young age, recurrent cryptogenic strokes or thrombosis, and unusual locations like the cerebral venous system. Laboratory clues such as unexplained erythrocytosis, thrombocytosis, thrombocytopenia, or hemolytic anemia should raise suspicion for an occult hematologic disorder. In the setting of acute illness, immune-mediated or heparin-induced thrombocytopenia or thrombotic microangiopathies should be suspected in patients that have hemorrhagic and or thrombotic complications, particularly when relevant lab disturbances are present. Acquired thrombophilia such as anti-phospholipid antibody syndrome should be considered in young patients with autoimmune disease, prior venous or arterial thrombotic complications, or pregnancy morbidity. Now, these are rare causes overall, but they're important to catch because the management can differ dramatically from our typical stroke care. Dr Nevel: Great. And what are some of the most common inherited or acquired thrombophilias and when should we be sending these labs? Dr Patrick: The hematologic causes really account for small minority of arterial strokes approximately one to two percent, but among those, sickle cell disease, anti-phospholipid antibody syndrome and the myeloproliferative neoplasms are the most common. Timing of testing is key. So, the genetic thrombophilia panels can be drawn at presentation, but lab values such as protein C, protein S, and antithrombin levels may be falsely low during acute thrombosis, so they're often repeated weeks later. Similarly, for anti-phospholipid antibody testing that should be done at presentation and when positive, confirmed at twelve weeks, since transient positivity can occur with affections or acute events. So, in patients that are already anticoagulated for anti-phospholipid antibody syndrome, testing becomes particularly tricky, especially with lupus anticoagulant assays. Some results need to be interpreted carefully or repeated when feasible. The main message is to collaborate early with our hematology colleagues to guide the timing and interpretation of these studies. Dr Nevel: Yeah, wonderful. Thank you. I'll ask some similar questions about neuropathy. So when should we consider an underlying hematologic disorder as being the cause for someone's neuropathy? Dr Terrelonge: So, luckily for a neurologist, then serum protein electrophoresis or an SPEP is already a part of the first pass evaluation for even the most common neuropathies we see, technically already considered every time we do an evaluation. However, we do know that most neuropathies progress very slowly and don't really lead to significant limitations in patient activities of daily living. And for those, the initial workup step, you may not need to do any additional search for any hematologic diseases after that first step. Within patients who start to have more unusual features with their neuropathy, including a rapid progression, early proximal weakness, significant and extremely painful neuropathies, significant ataxia, or new tremor or anything that's kind of outside of the garden variety neuropathy, then you should start to think about a hematologic cause. Additionally, if a patient already has a known hematologic malignancy or process before their neuropathy, there should be some form of assessment to see through exam or electrodiagnostically if the two are correlated. I do have to add one caveat, though, and that's just because someone has a hematologic malignancy or a paraprotein seen in their blood, their neuropathy and the neurologic syndrome don't necessarily have to be causally related. So, we have to do some additional testing to determine if the patient's presentation of the paraprotein are actually linked. Dr Nevel: Can you walk us through a little bit how we determine if they're associated or just coincidental? Dr Terrelonge: Yeah. So, for some of the proteins, there's a specific phenotype that will come with the specific protein. For example, an anti MAG proteinopathies or MAG standing for a myelin associated glycoprotein, it usually leads to a distal sensor and motor polyneuropathy where the most distal portions of nerves are affected. So, in that case, people might notice that they have numbness and weakness in their toes and their fingers, and it doesn't follow that typical length dependent pattern. So, in that case, if you have the anti mag neuropathy and the electrodiagnostic signature of an anti mag neuropathy along with the symptoms, you're more likely to think that the two are related then if not. Dr Nevel: Great. Thank you. And I was hoping you could speak a little bit more about amyloidosis just because I think that that's one that can be really tricky to diagnose. And I see patients, you know, have sometimes more drawn out evaluations or see multiple providers before a diagnosis is reached. So, can you speak a little bit more to how we diagnose amyloidosis in relationship to neuropathy or other neurological conditions and when we should push for more invasive testing like a nerve biopsy? Dr Terrelonge: So, amyloidosis certainly is a tricky diagnosis. I've been tricked by it and I think most of my neuromuscular colleagues have probably been tricked by it at least once. It's a hard diagnosis to make is it usually requires a pretty high index of suspicion, and also requires a tissue diagnosis to cinch. There're some patients who will come in with a prior history of amyloidosis and they're a little bit easier to figure out if the neuropathy is related. Maybe it's started in their heart or their kidney first and then you can just see if the type of amyloid they have usually deposits in nerve, and that may be enough. But if there's any diagnostic uncertainty, you could go forward with tissue biopsy. But it's patients in which the neuropathy is the first symptom that amyloidosis can be especially tricky to diagnose. It's a primarily light chain disease. So, if you do only an SPEP as a part of your initial neuropathy evaluation, you could miss it. But usually, the patients will have either a severely painful neuropathy, early autonomic dysfunction, or really prominent bilateral carpal tunnel syndrome. So, if they have any of those, usually we'll add in an amyloid workup as a part of that of the rest of the workup, which would include both light chain evaluations to see if there's any increase in Lambda or Kappa light chains and then also biopsy. Biopsy can be of the skin or fat pad first, which have reasonable sensitivity for picking up disease, but they're not necessarily a hundred percent. So if the suspicion remains high in those cases, a nerve biopsy should be considered. And the reason why this is important is that the chemotherapeutic agents that we have now can actually help arrest a lot of these diseases and stop further organ involvement. So, if you think about it, it is important to keep pushing and looking until you find it. Dr Nevel: Thank you so much for that. And a follow up question to that, once patients are started on appropriate therapy, the diagnosis is made, chemotherapy is started, what's the typical clinical course that you see in terms of their neuropathy? Do you ever see improvement or is it arrest of worsening? Dr Terrelonge: Usually for amyloid, there is an arrest of disease, but in some patients, they could have some improvement, not necessarily a dramatic improvement, but some patients could see some reversal of symptoms. That may not necessarily be because nerves injured nerves are regrowing, but because of reorganization of nerves to muscle, they could have some strength increases or at least less pain. Dr Nevel: Yeah, thank you. So, when should we involve a hematologist in aiding in the evaluation of patients we suspect may have an underlying hematological disorder? You guys really outlined very nicely in your article some of the laboratory workup or other workup like you just talked about with amyloidosis. But at what point in that workup should we reach out to our hematology colleagues? Dr Patrick: I would say almost always. So, these disorders are inherently multi-system and benefit from early co-management. In acute sickle cell stroke, for example, hematology helps direct emergent exchange transfusion. For myeloproliferative disorders they guide cyto reduction and long term antithrombotic strategy. And for antibody mediated or plasma cell disorders, hematology determines disease specific therapies. So, neurology may help with identifying the presentation, but the definitive management is almost always shared with our hematology colleagues. Dr Nevel: And as you both have mentioned that a lot of times in these cases, their hematologic disorder may be already known before they present with their neurological symptoms. So, I imagine obviously in those cases that a hematologist hopefully is already heavily involved in their care. What do you think is the most difficult aspect of identifying and diagnosing patients with neurologic illness as having an underlying hematological disorder? Dr Patrick: The hardest part is maintaining a high index of suspicion, especially since hematologic causes account for a very small minority of arterial strokes. Most strokes are from traditional vascular risk factors like you mentioned, or cardio embolism, so it's easy to stop diagnostic evaluation after standard studies have been performed. An example of a challenging case is a patient that's young, they've had recurrent cryptogenic stroke, and they could have antiphospholipid antibody syndrome, but it can be easy to miss if their antibody titers are borderline or if they're already anticoagulated, which would complicate retesting. So, it's about balancing the urge to over-test with recognizing the few cases where identifying A hematologic cause truly changes that management. Dr Terrelonge: And then on the neuropathy side, probably the hardest part is deciding what's causal and what's coincidence. Monoclonal gammopathy of unknown significance, or MGUS, is really common in older adults, so not every M-spike on an SPEP explains a neuropathy. And even sometimes there's times when the neurologic picture will develop a little bit faster than the hematologic one. So, it's hard to put the two together. Dr Nevel: Yeah. What's the most rewarding aspect of taking care of patients with complications from their hematologic disorders? Dr Patrick: It's deeply rewarding when a targeted diagnosis leads to a tangible improvement in that patient's care. For example, identifying A cryptogenic stroke is being due to myeloproliferative neoplasm or an inherited thrombophilia allows us to move from empiric treatment to possible disease specific strategy. It's really gratifying to give patients that clarity, to give them a diagnosis and in some cases prevent future events. Dr Terrelonge: Agreed. And even on the neuropathy side, almost all of the neuropathies that are hematologically related are treatable. So, it's so satisfying whenever you have a patient with say an anti-MAG neuropathy or Waldenström can start the patient on therapy, and you can see someone who's been having a progressive decline to stability and in those cases sometimes even significant recovery. Dr Nevel: Yeah, absolutely. Very rewarding when you can identify the problem and make it better. That's what it's all about. So, what are the future areas of research in this area? What do we still need to learn? Dr Patrick: There's still a lot to learn. I think we need better data on the safety of acute reperfusion therapy and antithrombotic agents, particularly in patients that are at dual risk for bleeding and thrombosis. Other examples, secondary prevention strategies and anti-phospholipid antibody syndrome. What's the best target INR? Do you add aspirin to warfarin or not? All of that is often left up to expert opinion. What's the best management for adults with sickle cell stroke? There are many open questions there. A lot of the protocols that we have in place for sickle cell patients that are adults as derived from pediatric literature and there's vast potential in terms of disease modifying therapies, especially in the fields of sickle cell disease and amyloidosis. And we'll need to reassess how those treatments may change neurologic outcomes. Dr Terrelonge: I think on the neuropathy side that having some form of new biomarkers to help us clearly know of the neuropathy and that hematologic illness are associated would be very helpful. On the treatment side, a lot of this is really being driven by the hematology space, but new therapies that treat hematologic plasma cell disorders, including some of the new BTK inhibitor, may be incorporated relatively soon into the algorithm for how we treat many of our patients. I'm excited to see what's to come from this. Dr Nevel: Wonderful. Thank you so much for sharing your knowledge with us today. I know I've certainly learned a lot by reading your article and through our discussion today. Highly encourage our listeners to read your wonderful article, which is a very thorough review of hematologic disorders and neurological complications. Again, today I've been interviewing Dr Lauren Patrick and Dr Mark Terrelonge on their article Neurologic Complications of Hematologic Disorders, which appears in the February 2026 Continuum issue on Neurology of Systemic Disease. Please be sure to check out Continuum Audio episodes from this and other issues. And as always, thank you so much to our listeners for joining today, and thank you so much to Lauren and Mark. Dr Terrelonge: Yeah, thank you so much for having us. Dr Patrick: Thank you so much for having us and for highlighting this topic. We hope the issue encourages clinicians to think broadly about hematologic causes of neurologic disease and to continue collaborating closely with our hematology colleagues. It's a complex but very fascinating intersection for both of our fields. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Perplexed by patients with normal exams but persistent symptoms like recurrent UTIs or palpitations? It could be menopause. In this insightful episode of Succeed In Medicine podcast, host Dr. Bradley Block interviews Dr. Lauren Streicher. They explore commonly overlooked menopause symptoms beyond hot flashes: recurrent urinary tract infections tied to genitourinary syndrome of menopause (GSM), palpitations as "hot flashes of the heart" (often sinus tachycardia without EKG changes), GI microbiome shifts causing nebulous digestive issues, xerostomia (dry mouth) linked to oral health risks, and skin/hair changes like alopecia. Dr. Streicher emphasizes reassuring patients early, validating symptoms as hormonal, and tailoring treatments, vaginal estrogen, safe even for breast cancer patients, systemic hormones, or new non-hormonal NK3 receptor antagonists like fezolinetant. They discuss the SWAN study's findings on long-term risks from untreated hot flashes (e.g., cardiovascular disease, bone loss), the need to differentiate perimenopausal (temporary) vs. lifelong postmenopausal effects, and avoiding arbitrary hormone therapy stops after 5 years. The conversation also touches on sexual health gaps in medicine, with tips for better history-taking and resources like Dr. Stryker's "Come Again" course. Listeners, clinicians and patients alike, will gain tools to address menopause holistically, improving quality of life and preventing complications. Three Actionable Takeaways: Recognize GSM in Recurrent UTIs: For postmenopausal women with new-onset recurrent UTIs, suspect genitourinary syndrome of menopause, prescribe local vaginal estrogen (cream, suppository, or ring) to restore microbiome and tissue health; it's safe for most, including breast cancer survivors on aromatase inhibitors. Reassure on Palpitations First: When midlife women present with palpitations, lead with "This is common in perimenopause (up to 50% affected) likely autonomic dysfunction like a 'heart hot flash'"; order a Holter monitor, but emphasize it's often benign and tied to vasomotor symptoms, treatable with hormones or NK3 antagonists. Integrate Sexual History Properly: Ditch "Are you sexually active?",  ask "Many women in menopause experience low libido, pain with sex, or orgasm difficulty; are any of these issues for you?"; refer to resources like Dr. Streicher's course for evaluation scripts, screeners, and solutions to address 50% of patients' unspoken concerns. About the Show: Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school! About the Guest: Dr. Lauren Streicher is a clinical professor of OB-GYN at Northwestern University and founding director of its Center for Sexual Medicine and Menopause. A certified menopause practitioner, she serves on the Menopause journal's editorial board, is a Kinsey Institute fellow, and authors bestsellers like "Sex Rx" and "Hot Flash Hell." She hosts "Inside Information" podcast and created "Come Again" audio series on postmenopausal sexuality. Connect with Dr. Lauren Streicher: Website: https://www.drstreicher.com Email: info@drstreicher.com  About the Host: Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physicians Want to be a guest? Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more! Socials: @physiciansguidetodoctoring on Facebook @physicianguidetodoctoring on YouTube @physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Artificial Intelligence in Medical Education: Opportunities, Risks, and GuardrailsIn this episode of The Pediatric Lounge, the hosts welcome back Dr. Rani Gareige, director of medical education and designated institutional official at Nicklaus Children's Hospital and a clinical professor at Florida International University, to discuss artificial intelligence in medical education now and in the future. They preview Nicklaus Children's Hospital's 61st annual postgraduate pediatrics CME conference in Fort Lauderdale (Hilton Marina Resort, March 20–22), highlighting sessions on IBD, short stature, dermatology, psychological screening, AI in practice management, social media communication, genetic testing/personalized medicine, and Florida's new requirement for EKG screening to clear athletes starting ninth grade. The conversation covers common AI tools learners use (ChatGPT, Claude, OpenEvidence) and institutional concerns about HIPAA/PHI, including blocking public tools and using a secure in-house system (“Ask Nick”) and closed or constrained approaches (e.g., tools that search only approved sources or documents provided, such as Google Notebook). They explore concerns about de-skilling and when to introduce AI in training, faculty development needs, and a precepting framework (DEFT-AI: Diagnosis, Evidence, Feedback, Teaching, and Recommendations for AI use) to assess clinical reasoning. The episode also discusses AI for simulated patient interactions (bad news delivery, motivational interviewing), ambient AI scribing pilots, clinician responsibility to review notes, and AI-driven coding that may reduce undercoding and administrative burden. The discussion concludes that AI will not replace physicians, but clinicians who use AI wisely may replace those who do not, stressing the importance of policies, ethics, transparency, and maintaining empathy and the art of medicine.00:00 Podcast Intro and Guest02:25 CME Conference Details03:13 Hot Topics and New Laws04:44 EKG Screening Program07:42 AI Tools in Training11:42 IRB and Data Privacy14:39 Meeting Minutes Automation16:48 Closed Models for Clinicians19:13 AI Hallucinations and References24:16 Deskilling and Timing AI30:11 Teaching Frameworks for AI32:46 Back to Evidence Basics33:40 Questioning the Evidence34:48 AI and Human Empathy37:45 AI as Clinical Assistant41:01 Recertification in the AI Era46:32 Ethics and Prompting50:40 AI Scribing and Guardrails54:35 Coding and Care Gaps57:15 Future of Medical Education01:01:13 Virtual Trials and Wrap-Up01:0Support the show

Send a textThere are practices that look profitable on paper and still feel constantly on edge.Payroll clears, but just barely. Distributions feel risky. Hiring decisions get delayed. Big expenses create anxiety instead of confidence. And despite doing “well,” leadership always feels like they're waiting for the other shoe to drop.That feeling usually has nothing to do with profit.It has everything to do with cash flow.Cash flow tells the truth in a way no other financial statement does. Revenue tells you what you earned. Profit tells you what's left after expenses. But cash flow tells you whether you're actually safe—and what the next twelve months are likely to feel like.Today, we're talking about what your financials are saying about your future, why cash flow forecasting is one of the most underused leadership tools in medicine, and why having three forecasts—not one—is what separates confident practices from reactive ones.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/

In this episode, Drs. Jason Silverman and Jennifer Lee talk to Dr. Paul Wales all about the surgical management of short bowel syndrome, including decision-making based on initial presentation and important considerations for any autologous reconstruction procedure.Learning objectivesTo define intestinal failure, short bowel syndrome and ultrashort bowel syndrome as well as surgical subtypes of short bowel syndromeTo review surgical considerations in the staged management of short bowel syndromeTo discuss surgical approaches to autologous bowel reconstruction including their potential advantages and disadvantages LinksPapers mentioned:Surgical therapy for short bowel syndrome (review with images)Establishing norms for intestinal length in childrenPredicting Intestinal Adaptation in Pediatric Intestinal FailureAdvantages of the distal sigmoid colostomyDelayed primary STEP procedurePrevious episodes mentioned:Sue Protheroe - Enteral Nutrition in Intestinal FailureDanielle Wendel - Central Line Management in Intestinal Failure (Special JPGN Episode)Ruben Quiros-Tejeira - Multivisceral TransplantationSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Deescalating difficult situations can feel like an art. Listen as hosts John, Drew, and Andy discuss the art of Mastering Conflict in the ED. Don't forget we are the official podcast of the American College of Osteopathic Emergency Physicians. Visit acoep.org today to learn more about an upcoming CME event and how you can see your favorite EM podcast LIVE and in person.

Featuring an interview with Dr Terence Friedlander, including the following topics: Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00) Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17) TROP2-targeted antibody-drug conjugates for locally advanced or metastatic urothelial carcinoma (18:19) CME information and select publications

Crypto News: Soil launches RLUSD yield protocol on XRP Ledger. Societe Generale launches EUR CoinVertible on the XRPL. Ripple CEO Brad Garlinghouse: 80% Chance the CLARITY Act Clears Congress by April!. White House urges bankers to allow for limited stablecoin rewards to advance the Bitcoin and crypto market structure legislation.Brought to you by